Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model
暂无分享,去创建一个
R. Caprioli | N. Verbeeck | J. L. Norris | N. H. Patterson | Rami N. Al-Rohil | Margaret L. Compton | J. Robbins | A. Alomari | Marc Claesen | S. Kantrow | J. Moore | M. Claesen | Sarah P Nicholson | Jameelah Z Muhammad | R. Al-Rohil | N. Patterson
[1] Ryanne A. Brown,et al. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features , 2020, Journal of cutaneous pathology.
[2] K. Linos,et al. Concordance Analysis of the 23-Gene Expression Signature (myPath Melanoma) With Fluorescence In Situ Hybridization Assay and Single Nucleotide Polymorphism Array in the Analysis of Challenging Melanocytic Lesions: Results From an Academic Medical Center. , 2020, The American Journal of dermatopathology.
[3] D. Elder,et al. Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. , 2020, Personalized medicine.
[4] K. Busam,et al. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors , 2020, The American journal of surgical pathology.
[5] A. Andea. Updates on molecular diagnostic assays in melanocytic pathology , 2020 .
[6] L. Lowe,et al. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach , 2020, Modern Pathology.
[7] A. Andea,et al. Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis , 2020, Modern Pathology.
[8] W. High,et al. Immunohistochemistry utilization in the diagnosis of melanoma , 2020, Journal of cutaneous pathology.
[9] R. Gueorguieva,et al. Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma , 2019, Journal of cutaneous pathology.
[10] Carsten Denkert,et al. MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods , 2018, Proteomics. Clinical applications.
[11] Jannis Teunissen,et al. Tumor classification with MALDI-MSI data of tissue microarrays: A case study. , 2018, Methods.
[12] K. Nehal,et al. PRAME Expression in Melanocytic Tumors , 2018, American Journal of Surgical Pathology.
[13] C. Lian,et al. Molecular Testing for Cutaneous Melanoma: An Update and Review. , 2018, Archives of pathology & laboratory medicine.
[14] R. Caprioli,et al. Advanced Registration and Analysis of MALDI Imaging Mass Spectrometry Measurements through Autofluorescence Microscopy. , 2018, Analytical chemistry.
[15] Richard M Caprioli,et al. Next Generation Histology-Directed Imaging Mass Spectrometry Driven by Autofluorescence Microscopy. , 2018, Analytical chemistry.
[16] E. Velazquez,et al. Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms , 2018, Modern Pathology.
[17] V. Adam,et al. MALDI MSI of MeLiM melanoma: Searching for differences in protein profiles , 2017, PloS one.
[18] K. Schey,et al. MALDI (matrix assisted laser desorption ionization) Imaging Mass Spectrometry (IMS) of skin: Aspects of sample preparation. , 2017, Talanta.
[19] E. Seeley,et al. Proteomic Mass Spectrometry Imaging for Skin Cancer Diagnosis. , 2017, Dermatologic clinics.
[20] M. Weinstock,et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study , 2017, British Medical Journal.
[21] H. Kimbrell,et al. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[22] R. Caprioli,et al. Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. , 2016, Journal of the American Academy of Dermatology.
[23] J. Elmore,et al. Achieving consensus for the histopathologic diagnosis of melanocytic lesions: use of the modified Delphi method , 2016, Journal of cutaneous pathology.
[24] Danielle B. Gutierrez,et al. Pathology interface for the molecular analysis of tissue by mass spectrometry , 2016, Journal of pathology informatics.
[25] P. Marcorelles,et al. A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma , 2015, Diagnostic Pathology.
[26] R. Caprioli,et al. Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma – diagnosis supported by sex chromosome analysis and Imaging Mass Spectrometry , 2015, Journal of cutaneous pathology.
[27] Matthew Hand,et al. Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches. , 2015, Journal of the American Academy of Dermatology.
[28] R. Caprioli,et al. Histology-directed and imaging mass spectrometry: An emerging technology in ectopic calcification. , 2015, Bone.
[29] C. Lian,et al. Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update , 2015, Dermatopathology.
[30] A. Gutin,et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma , 2015, Journal of cutaneous pathology.
[31] A. Viale,et al. A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation. , 2013, The Journal of molecular diagnostics : JMD.
[32] Heinz Höfler,et al. MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. , 2013, Clinical biochemistry.
[33] S. South,et al. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements. , 2012, Archives of pathology & laboratory medicine.
[34] R. Hofmann-Wellenhof,et al. Agreement of Dermatopathologists in the Evaluation of Clinically Difficult Melanocytic Lesions: How Golden Is the ‘Gold Standard’? , 2012, Dermatology.
[35] Richard M Caprioli,et al. Imaging Mass Spectrometry—A New and Promising Method to Differentiate Spitz Nevi From Spitzoid Malignant Melanomas , 2012, The American Journal of dermatopathology.
[36] R. Caprioli,et al. Spatial mapping by imaging mass spectrometry offers advancements for rapid definition of human skin proteomic signatures , 2011, Experimental dermatology.
[37] Richard M Caprioli,et al. Protein signatures for survival and recurrence in metastatic melanoma. , 2011, Journal of proteomics.
[38] L. Cerroni,et al. Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases , 2011, Modern Pathology.
[39] R. Scolyer,et al. Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? , 2011, Archives of pathology & laboratory medicine.
[40] A. Enk,et al. Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up , 2010, Modern Pathology.
[41] M. Mihm,et al. The dermal-based borderline melanocytic tumor: a categorical approach. , 2010, Journal of the American Academy of Dermatology.
[42] L. Morrison,et al. Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma , 2009, The American journal of surgical pathology.
[43] P. Spellman,et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.
[44] Yu Shyr,et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.
[45] P. Leboit,et al. Histological Diagnosis of Nevi and Melanoma , 2004, Steinkopff.
[46] R. Caprioli,et al. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. , 1997, Analytical chemistry.
[47] W. Mooi,et al. Quality assessment by expert opinion in melanoma pathology: experience of the Pathology Panel of the Dutch Melanoma Working Party , 1997, The Journal of pathology.
[48] M. Tetzlaff,et al. Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry. , 2017, Actas dermo-sifiliograficas.
[49] D. Jukic,et al. Discrepancies in dermatopathology diagnoses: the role of second review policies and dermatopathology fellowship training. , 2013, Journal of the American Academy of Dermatology.
[50] Vladimir Vapnik,et al. Support-vector networks , 2004, Machine Learning.